Hypertrophic cardiomyopathy in childhood

Pediatric Clinics of North America

Volumn 51, Issue 5, 2004, Pages 1305-1346

  Maron, Barry J ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DISOPYRAMIDE; INOTROPIC AGENT; METOPROLOL; NADOLOL; PROPRANOLOL; VERAPAMIL;

AGE DISTRIBUTION; AORTA OCCLUSION; ATHLETE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOARCHITECTURE; DEFIBRILLATOR; DEPRESSION; DISEASE COURSE; DNA DETERMINATION; ECHOCARDIOGRAPHY; FAMILY HISTORY; GENE MUTATION; GENETICS; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HEART VENTRICLE EJECTION; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LABORATORY DIAGNOSIS; MOLECULAR GENETICS; MORPHOLOGY; MORTALITY; MUSCLE RESECTION; PHENOTYPE; PREVALENCE; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SEX RATIO; SIDE EFFECT; STROKE; SUDDEN DEATH; SURGICAL TECHNIQUE; SYSTOLIC HEART MURMUR; WOLFF PARKINSON WHITE SYNDROME;

CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; PHENOTYPE; PROGNOSIS; RISK FACTORS; SPORTS; TERMINOLOGY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 4344607459     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2004.04.017     Document Type: Review

References (127)

1. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 42:2003;1687-1713
2. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 348:2003;295-303
3. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 20:1958;1-18
4. Braunwald E., Lambrew C.T., Rockoff D., et al. Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients. Circulation. 30(Suppl IV):1964;3-217
5. Frank S., Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation. 37:1968;759-788
6. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA. 287:2002;1308-1320
7. Maron B.J., Bonow R.O., Cannon R.O., et al. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:780-9 and 844-52
8. Wigle E.D., Sasson Z., Henderson M.A., et al. Hypertrophic cardiomyopathy: the importance of the site and extent of hypertrophy. A review. Prog Cardiovasc Dis. 28:1985;1-83
9. Spirito P., Seidman C.E., McKenna W.J., et al. Management of hypertrophic cardiomyopathy. N Engl J Med. 30:1997;775-785
10. Wigle E.D., Rakowski H., Kimball B.P., et al. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 92:1995;1680-1692
11. Maron B.J., Moller J.H., Seidman C.E., et al. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. Circulation. 98:1998;1460-1471
12. Schwartz K., Carrier L., Guicheney P., et al. Molecular basis of familial cardiomyopathies. Circulation. 91:1995;532-540
13. Niimura H., Bachinski L.L., Sangwatanaroj S., et al. Mutations in the gene for human cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 338:1998;1248-1257
14. Maron B.J., Estes N.A.M. III, Maron M.S., et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 107:2003;2872-2875
15. Maron B.J. Hypertrophic cardiomyopathy: an important global disease [editorial]. Am J Med. 116:2004;63-65
16. Panza J.A., Maron B.J. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 63:1989;1258-1265
17. Maron B.J., Gottdiener J.S., Epstein S.E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide-angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol. 48:1981;418-428
18. Klues H.G., Roberts W.C., Maron B.J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. Circulation. 84:1991;1188-1197
19. Klues H.G., Maron B.J., Dollar A.L., et al. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 85:1992;1651-1660
20. Klues H.G., Schiffers A., Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 26:1995;1699-1708
21. Elliott P.M., Gimeno J.R., Mahon N.G., et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 357:2001;420-424
22. Elliott P.M., Poloniecki J., Dickie S., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 36:2000;2212-2218
23. Yetman A.T., McCrindle B.W., MacDonald L.C., et al. Myocardial bridging in children with hypertrophic cardiomyopathy - a risk factor for sudden death. N Engl J Med. 339:1998;1201-1209
24. Maron B.J., Casey S.A., Hurrell D.G., et al. Relation of left ventricular hypertrophy to age and gender in hypertrophic cardiomyopathy. Am J Cardiol. 91:2003;1195-1198
25. Maron B.J., Spirito P., Wesley Y., et al. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 315:1986;610-614
26. Maron B.J., Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol. 81:1998;1339-1344
27. Maron B.J., Harding A.M., Spirito P., et al. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in hypertrophic cardiomyopathy. Circulation. 68:1983;282-293
28. Kofflard M.J., ten Cate F.J., van der Lee C., et al. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol. 41:2003;987-993
29. Monserrat L., Elliott P.M., Gimeno J.R., et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 42:2003;873-879
30. Maron B.J., Casey S.A., Poliac L.C., et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 281:1999;650-655
31. Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol. 13:1989;1283-1288
32. Cecchi F., Olivotto I., Gistri R., et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 349:2003;1027-1035
33. Spirito P., Chiarella F., Carratino L., et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 320:1989;749-755
34. Spirito P., Bellone P., Harris K.M., et al. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 342:2000;1778-1785
35. Basso C., Thiene G., Corrado D., et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol. 31:2000;988-998
36. Hecht G.M., Klues H.G., Roberts W.C., et al. Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 22:1993;489-497
37. Cecchi F., Olivotto I., Montereggi A., et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol. 26:1995;1529-1536
38. Ferrans V.J., Morrow A.G., Roberts W.C. Myocardial ultrastructure in idiopathic hypertrophic subaortic stenosis: a study of operatively excised left ventricular outflow tract muscle in 14 patients. Circulation. 45:1972;769-792
39. Maron B.J., Roberts W.C. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation. 59:1979;689-706
40. Shah P.M., Taylor R.D., Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve. Am J Cardiol. 48:1981;258-262
41. Moolman J.C., Corfield V.A., Posen B., et al. Sudden death due to troponin T mutations. J Am Coll Cardiol. 29:1997;549-555
42. Maron B.J., Henry W.L., Clark C.E., et al. Asymmetric septal hypertrophy in childhood. Circulation. 53:1976;9-19
43. Maron B.J., Shen W.-K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 342:2000;365-373
44. Silka M.J., Kron J., Dunnigan A., et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation. 87:1993;800-807
45. Elliott P.M., Sharma S., Varnava A., et al. Survival after cardiac arrest in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 33:1999;1596-1601
46. Nicod P., Polikar R., Peterson K.L. Hypertrophic cardiomyopathy and sudden death. N Engl J Med. 318:1988;1255-1257
47. McKenna W.J., Deanfield J.E. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child. 59:1984;971-975
48. Maron B.J. Sudden death in young athletes. N Engl J Med. 349:2003;1064-1075
49. Saumarez R.C., Chojnowska L., Derksen R., et al. Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation. 107:2003;2595-2600
50. Maki S., Ikeda H., Muro A., et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 82:1998;774-778
51. Maron B.J., Gardin J.M., Flack J.M., et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation. 92:1995;785-789
52. Zou Y., Song L., Wang Z., et al. Prevalence of idiopathic hypertrophic cardiomyopathy in Chinese - a cross-sectional population based echocardiographic analysis of 8080 adults. Am J Med. 116:2004;14-18
53. Maron B.J., Peterson E.E., Maron M.S., et al. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 73:1994;577-580
54. Maron B.J. Hypertrophic cardiomyopathy. Lancet. 350:1997;127-133
55. Watkins H., McKenna W.J., Thierfelder L., et al. The role of cardiac troponin T and α-tropomyosin mutations in hypertrophic cardiomyopathy. N Engl J Med. 332:1995;1058-1064
56. Maron B.J., Niimura H., Casey S.A., et al. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C mutations. J Am Coll Cardiol. 38:2001;315-321
57. Anan R., Greve G., Thierfelder L., et al. Prognostic implications of novel β-cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 93:1994;280-285
58. Charron P., Dubourg O., Desnos M., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 97:1998;2230-2236
59. Richard P., Charron P., Carrier L., et al. Hypertrophic cardiomyopathy. Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 107:2003;2227-2232
60. McKenna W.J., Spirito P., Desnos M., et al. Experience from clinical genetics in hypertrophic cardiomyopathy: Proposal for new diagnostic criteria in adult members of affected families. Heart. 77:1997;130-132
61. Hagège A.A., Dubourg O., Desnos M., et al. Familial hypertrophic cardiomyopathy: cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. Eur Heart J. 19:1998;489-498
62. Ackerman M.J., Van Driest S.L., Ommen S.R., et al. Prevalence and age dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol. 39:2002;2042-2048
63. Van Driest S.L., Ackerman M.J., Ommen S.R., et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 106:2002;3085-3090
64. Seidman J.G., Seidman C.E. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 104:2001;557-567
65. Arad M., Benson D.W., Perez-Atayde A.R., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 109:2002;357-362
66. Arad M., Maron B.J., Gorham J.M., et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med, in press
67. Varnava A.M., Elliott P.M., Baboonian C., et al. Hypertrophic cardiomyopathy. Histopathological features of sudden death in cardiac troponin T disease. Circulation. 104:2001;1380-1384
68. Ho C.Y., Sweitzer N.K., McDonough B., et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 105:2002;2992-2997
69. Maron B.J., Seidman J.G., Seidman C.E. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;. in press
70. Louie E.K., Maron B.J. Apical hypertrophic cardiomyopathy: clinical and two-dimensional echocardiographic assessment. Ann Intern Med. 106:1987;663-670
71. Webb J.G., Sasson Z., Rakowski H., et al. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol. 15:1990;83-90
72. Maron B.J., Mathenge R., Casey S.A., et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 33:1999;1590-1595
73. Maron B.J., Casey S.A., Almquist A.K. Extreme hypertrophic cardiomyopathy. Heart. 90:2004;24
74. Maron B.J., Piccininno M., Casey S.A., et al. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol. 91:2003;626-628
75. Maron B.J., Pelliccia A., Spirito P. Cardiac disease in young trained athletes: Insights into methods for distinguishing athlete's heart from structural heart disease with particular emphasis on hypertrophic cardiomyopathy. Circulation. 91:1995;1596-1601
76. Rickers C., Wilkie N.M., Casey S., et al. Identification of hypertrophic cardiomyopathy by magnetic resonance imaging in the absence of echocardiographic diagnosis. Circulation. 106(Suppl II):2002;II-652-II-653
77. Maron B.J. The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited [editorial]. Ann Noninvas Electrocardiol. 6:2001;277-279
78. Corrado D., Basso C., Schiavon M., et al. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 339:1998;364-369
79. Montgomery J.V., Gohman T.E., Harris K.M., et al. Electrocardiogram in hypertrophic cardiomyopathy revisited: does ECG pattern predict phenotypic expression and left ventricular hypertrophy or sudden death? J Am Coll Cardiol. 39(Suppl A):2002;161A
80. Watkins H. Sudden death in hypertrophic cardiomyopathy [editorial]. N Engl J Med. 372:2000;422-423
81. Panza J.A., Maris T.J., Maron B.J. Development and determinants of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. Circulation. 85:1992;1398-1405
82. Obeid A.I., Maron B.J. Apical hypertrophic cardiomyopathy developing at a relatively advanced age. Circulation. 103:2001;1605
83. Varnava A.M., Elliott P.M., Mahon N., et al. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 88:2001;275-279
84. Maron B.J., Wolfson J.K., Epstein S.E., et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 8:1986;545-557
85. Cannon R.O., Rosing D.R., Maron B.J., et al. Myocardial ischemia in hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 71:1985;234-243
86. Shirani J., Pick R., Roberts W.C., et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 35:2000;36-44
87. Maron B.J., Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol. 72:1993;970-972
88. Spirito P., Rapezzi C., Autore C., et al. Prognosis in asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation. 90:1994;2743-2747
89. Schaffer M.S., Freedom R.M., Rowe R.D. Hypertrophic cardiomyopathy presenting before 2 years of age in 13 patients. Pediatr Cardiol. 4:1983;113-119
90. Maron B.J., Tajik A.J., Ruttenberg H.D., et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation. 65:1982;7-17
91. Skinner J.R., Manzoor A., Hayes A.M., et al. A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. Heart. 77:1997;229-233
92. Meyer M., De Moor M.M.A., Human D.G. Hypertrophic cardiomyopathy in infancy and childhood. S Afr Med J. 71:1987;490-493
93. Comparato C., Pipitone S., Sperandeo V., et al. Clinical profile and prognosis of hypertrophic cardiomyopathy when first diagnosed in infancy as opposed to childhood. Cardiol Young. 7:1997;410-416
94. Maron B.J., Verter J., Kapur S. Disproportionate ventricular septal thickening in the developing normal human heart. Circulation. 57:1978;520-526
95. Holmgren D., Wåhlander H., Eriksson B.O., et al. Cardiomyopathy in children with mitochondrial disease. Clinical course and cardiological findings. Eur Heart J. 24:2003;280-288
96. Kohlschütter A., Hausdorf G. Primary (genetic) cardiomyopathies in infancy. A survey of possible disorders and guidelines for diagnosis. Eur J Pediatr. 145:1986;454-459
97. Lipshultz S.E., Sleeper L.A., Towbin J.A., et al. The incidence of pediatric cardiomyopathy in two regions in the United States. N Engl J Med. 348:2003;1647-1655
98. Nugent A.W., Daubeney P.E.F., Chondros P., et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 348:2003;1639-1646
99. Arola A., Jokinen E., Ruuskanen O., et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol. 146:1997;385-393
100. Miura K., Nakagawa H., Morikawa Y., et al. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. Heart. 87:2002;126-130
101. Sherrid M.V., Chu C.K., Delia E., et al. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 22:1993;816-825
102. Kizilbas A.M., Heinle S.K., Grayburn P.A. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic cardiomyopathy. Circulation. 97:1998;461-466
103. Olivotto I., Cecchi F., Casey S.A., et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 104:2001;2517-2524
104. Maron B.J., Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large non-referral-based patient population. Circulation. 102:2000;858-864
105. Cecchi F., Olivotto I., Montereggi A., et al. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart. 79:1998;331-336
106. McKenna W.J., Franklin R.C.G., Nihoyannopoulos P., et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 11:1988;147-153
107. Olivotto I., Maron B.J., Montereggi A., et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 33:1999;2044-2051
108. Sorajja P., Ommen S.R., Nishimura R.A., et al. Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 42:2003;889-894
109. Mohiddin S.A., Begley D., Shih J., et al. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol. 36:2000;2270-2278
110. Jayatilleke I., Doolan A., McGuire M., et al. Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: long-term follow-up study in an Australian population. Am J Cardiol. 93:2004;1192-1194
111. Gregoratos G., Abrams J., Epstein A.E., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 106:2002;2145-2161
112. Maron B.J., Isner J.M., McKenna W.J. Hypertrophic cardiomyopathy, myocarditis and other myopericardial disease, and mitral valve prolapse. Task Force 3. In: 26th Bethesda Conference. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. J Am Coll Cardiol. 24:1994;880-885
113. Maron B.J., Spirito P., Green K.J., et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 10:1987;733-742
114. Nihoyannopoulos P., Karatasakis G., Frenneaux M., et al. Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol. 19:1992;536-540
115. Bonow R.O., Rosing D.R., Bacharach S.L., et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 64:1981;787-795
116. Spicer R.L., Rocchini A.P., Crowley D.C., et al. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. Am J Cardiol. 53:1984;1614-1619
117. Sherrid M., Delia E., Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 62:1988;1085-1088
118. Östman-Smith I., Wettrell G., Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose β-adrenoceptor antagonist treatment. J Am Coll Cardiol. 34:1999;1813-1822
119. Spirito P., Rapezzi C., Bellone P., et al. Infective endocarditis in hypertrophic cardiomyopathy. Prevalence, incidence and indications for antibiotic prophylaxis. Circulation. 99:1999;2132-2137
120. Morrow A.G., Reitz B.A., Epstein S.E., et al. Operative treatment in hypertrophic subaortic stenosis: techniques and the results of pre- and postoperative assessments in 83 patients. Circulation. 52:1975;88-102
121. Williams W.G., Wigle E.D., Rakowski H., et al. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation. 76(Suppl V):1987;104-108
122. Theodoro D.A., Danielson G.K., Feldt R.H., et al. Hypertrophic cardiomyopathy in pediatric patients: results of surgical treatment. J Thorac Cardiovasc Surg. 112:1996;1589-1599
123. Maron B.J., Nishimura R.A., Danielson G.K. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 98:1998;2505-2508
124. Ommen S.R., Olivotto I., Betocchi S., et al. The effect of surgical myectomy on survival of patients with hypertrophic cardiomyopathy [abstract]. J Am Coll Cardiol. 43(Suppl A):2004;215A
125. Maron B.J., Nishimura R.A., McKenna W.J., et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind cross-over study (M-PATHY). Circulation. 99:1999;2927-2933
126. Kimmelstiel C.D., Maron B.J. Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy: role within the treatment armamentarium and other considerations. Circulation. 109:2004;452-455
127. Shirani J., Maron B.J., Cannon R.O., et al. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol. 72:1993;434-440